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Abstract Bone metabolism appears to influence insulin secretion and sensitivity, and insulin 
promotes bone formation in animals, but similar evidence in humans is limited. The objectives of 
this study are to explore if bone turnover markers were associated with insulin secretion and 
sensitivity and to determine if bone turnover markers predict changes in insulin secretion and 
sensitivity. The study population encompassed 576 non-diabetic adult men with normal glucose 
tolerance (NGT; n=503) or impaired glucose regulation (IGR; n=73). Baseline markers of bone 
resorption (CTX) and formation (P1NP) were determined in the fasting state and after a 2-hour 
hyperinsulinaemic, euglycaemic clamp. An intravenous glucose tolerance test (IVGTT) and a 2-
hour oral glucose tolerance test (OGTT) were performed at baseline, and the OGTT was repeated 
after 3 years. There were no differences in bone turnover marker levels between NGT and IGR. 
CTX and P1NP levels decreased by 8.0% (p<0.001) and 1.9% (p<0.01) between baseline and 
steady-state during the clamp. Fasting plasma glucose was inversely associated with CTX and 
P1NP both before and after adjustment for recruitment centre, age, BMI, smoking and physical 
activity. However, baseline bone turnover markers were neither associated with insulin sensitivity 
(assessed using hyperinsulinaemic euglycaemic clamp and OGTT) nor with insulin secretion 
capacity (based on IVGTT and OGTT) at baseline or at follow-up. Although inverse associations 
between fasting glucose and markers of bone turnover were identified, this study cannot support an 
association between insulin secretion and sensitivity in healthy, non-diabetic men.  
 
Keywords: P1NP, CTX, insulin, sensitivity, secretion 
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Introduction 
Fracture risk is increased in people with type 2 diabetes (T2D) despite bone mass generally being 
normal or increased.[1] Clinical studies revealed decreased levels of circulating biochemical 
markers of bone formation and resorption in individuals with T2D[1] as well as lower bone 
formation and resorption and lower bone quality in bone biopsies in T2D.[2] The mechanisms 
behind these changes in bone turnover and the increased risk of fracture in T2D are not fully 
elucidated.  
Inadequate secretion of insulin and insulin resistance are the cornerstones in the development of 
T2D. Insulin is considered bone anabolic due to stimulatory effects on osteoblast differentiation,[3] 
and mice not expressing the insulin receptor in osteoblasts have low bone mass.[4] Insulin 
signalling in osteoblasts favours osteoclast bone resorption activity through secretion of 
osteoprotegerin and, subsequently, generation and release of the undercarboxylated form of 
osteocalcin, an osteoblast-secreted marker of bone formation, which may stimulate insulin secretion 
from the pancreatic β-cells.[5] Furthermore, hyperglycaemia impairs osteoblast activity and 
survival[6-8] and promotes adipogenic rather than osteogenic differentiation of adipose and muscle-
derived stem cells.[9] Additionally, gain-and-loss-of-function models of insulin signalling in mice 
osteoblasts provide evidence that a high fat diet causes insulin resistance in bone, which lowers 
bone turnover and osteocalcin activity, causing higher bone volume and glucose intolerance in 
mice.[10]  
Thus, based on preclinical investigations, insulin levels and beta-cell function as well as insulin 
sensitivity would be expected to correlate with markers of bone formation in humans, but clinical 
data from non-diabetic individuals remain to be established. Integration of bone and glucose 
homeostasis in humans is supported by direct associations between total osteocalcin and estimates 
of insulin secretion and sensitivity based on oral and intravenous glucose tolerance tests (OGTT or 
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IVGTT)[11-14] and inverse associations with plasma glucose in T2D,[15] age-related increases in 
plasma glucose,[13] and incidence of T2D[16-18]. Also, markers of bone resorption but not bone 
formation were inversely associated with the incidence of T2D.[17] However, other investigations 
have not provided support of associations between total osteocalcin and plasma glucose or incident 
diabetes[19-22]. Although the increased levels of fasting insulin usually observed in early stages of 
T2D could promote bone formation and subsequently bone resorption due to coupling of bone 
formation and resorption, possibly explaining the association between bone mineral density (BMD) 
and fasting insulin levels observed in some[23, 24] but not all epidemiological studies of non-
diabetic individuals,[25] insulin resistance in bone cells may reduce bone formation and resorption, 
which are reported to be lower in patients with T2D.[1, 26] Corroborating these reports, insulin 
sensitivity assessed by an IVGTT was inversely associated with BMD in a selected group of non-
diabetic, generally obese men with heart disease,[27] and homeostasis model assessment of insulin 
resistance (HOMA-IR) was positively associated with volumetric BMD in postmenopausal, non-
diabetic women.[28] While these studies suggest that insulin resistance may increase bone mass, 
possibly due to lower bone turnover in T2D[26], it remains unknown if insulin sensitivity measured 
using the gold standard, i.e. the hyperinsulinaemic, euglycaemic clamp and insulin secretion 
assessed by OGGT or IVGTT, are associated with bone turnover in non-diabetic individuals. 
The aim of this study was to investigate the relationship between bone turnover using markers of 
bone resorption (CTX) and formation (P1NP), and insulin secretion and sensitivity assessed with 
the hyperinsulinaemic euglycaemic clamp and measures derived from intravenous and oral glucose 
tolerance tests in clinically healthy, non-diabetic men. Furthermore, we explored if bone turnover 
was associated with insulin secretion and 3-year changes in insulin secretion and sensitivity.  
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Materials and methods 
The Relationship between Insulin Sensitivity and Cardiovascular Risk Study (RISC) is a 
prospective cohort study conducted at 19 European research centres across 14 European 
countries.[29] Baseline and 3-year follow-up data were included in the present study. In short, 
between 2002 and 2004, 1,556 clinically healthy female and male volunteers aged 29-61 years were 
recruited from the local community. Individuals being treated for obesity, diabetes, hypertension or 
lipid disorders were excluded from participation. The exclusion criteria comprised recent weight 
change (>5 kg) or major surgery, chronic pulmonary and cardiovascular diseases, renal failure 
including renal transplant, seizure disorders including epilepsy, steroid treatment, and any diagnosis 
of cancer in the previous 5 years but not osteoporosis or treatment for osteoporosis. After physical 
examination, biochemical testing and a 75-gram 2-hour OGTT were performed. Individuals with 
increased fasting or 2-hour glucose levels (≥ 7 and 11.1 mmol/l, respectively), increased blood 
pressure (≥140/90 mmHg) or increased lipids (triglyceride ≥4.6 mmol/l and total cholesterol ≥7.8 
mmol/l) were excluded.[29] In order to limit the effects of factors known or anticipated to influence 
bone and glucose homeostasis such as menstrual cycle, only male participants of the RISC study 
were selected for the present investigation. 
Anthropometrics and lifestyle 
Body height was measured using a standard ruler (stadiometer) without shoes. Waist size was 
measured on bare skin at the smallest point between costal edges and the iliac crest. Body weight 
and fat free mass (FFM) were measured with participants in light clothes and in the fasting state 
using a Tanita bioimpedence TBF-300 body composition analyser (Tanita International, United 
Kingdom). Physical activity was registered by the 7-day International Physical Activity 
Questionnaire (IPAQ) and used to calculate metabolic equivalent energy expenditure per week. The 
level of physical activity was explored both as a continuous and a categorical measure as the study 
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population was categorized in three groups based on their level of physical activity (inactive, 
minimally active and health enhancing physical activity). Smoking status was dichotomized 
according to whether the participant reported current use of tobacco products. 
Assessment of glucose homeostasis 
All participants underwent a 75-gram OGTT after an overnight fast, with samples being collected at 
after 0, 30, 60, 90 and 120 minutes, at baseline and at 3 years. At baseline, hyperinsulinaemic 
euglycaemic clamp was performed within one week of the OGTT. During the clamp, insulin was 
infused at a rate of 240 pmol per min per square meter, and infusion of dextrose (20%) was 
modified at 5-10 minutes intervals in order to keep plasma glucose levels within 0.8 mmol/L of 4.5-
5.5 mmol/L. To evaluate first phase insulin secretion, an intravenous glucose tolerance test 
(IVGTT) was performed after the clamp in a subset of the participants (n=438 men). A weight-
adjusted dose of glucose (0.3g per kg bodyweight) was infused in one minute, and samples were 
subsequently collected after 2, 4, 6 and 8 minutes.  
Biochemical tests 
Blood samples were separated into serum and plasma and stored at -80 degrees until biochemical 
tests were performed. Samples were transferred on dry ice between sites and laboratories. Glucose 
was measured using the glucose oxidase technique (Cobas Integra, Roche) (within- and between 
assay coefficients of variation: 1.8% and 2.1%). Serum insulin and C-peptide were assessed using a 
two-sided time-resolved flouroimmunoassay (AutoDELFIA, Insulin Kit, Wallac Oy, Turku, 
Finland) based on monoclonal antibodies (Within and between assay coefficients of variation: 
Insulin (normal levels): 4.3% and 3.7%. C-peptide (normal levels): 5.3% and 2.6%). Serum 
Procollagen type I amino-terminal propeptide (PINP) and C-telopeptide of type I collagen (CTX-1) 
were measured by the chemiluminescence method in the fasting state and at steady-state of a 
euglycaemia during the clamp (IDS-iSYS. Within and between assay coefficients of variation (CV): 
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PINP: 7% and 7%. CTX-1: 5% and 18%). Vitamin D was measured using direct competitive 
electrochemiluminescence immunoassay (COBAS 311, Roche). 
Insulin sensitivity and beta-cell function 
Based on the OGTT, participants were classified into two groups, individuals with normal glucose 
tolerance (NGT) or impaired glucose regulation (IGR), which included individuals with impaired 
fasting glycaemia (6.1-6.9 mmol/l), impaired glucose tolerance (2-hour-OGTT glucose levels 
between 7.8 and 11.0 mmol/l) and a combination of both. Insulin sensitivity was calculated as the 
ratio of the average glucose infusion rate during the last 40 minutes of the 2-hour clamp (adjusted 
for fat-free mass), M, and mean insulin levels during the same time interval (M/I). At both baseline 
and the 3-year follow-up, insulin sensitivity was assessed using plasma glucose and insulin levels 
measured during the 2-hour-OGTT at baseline and follow-up. We used the oral glucose insulin 
sensitivity index normalized to lean body mass optimized for the RISC-study (OGIS-RISC), which 
has been shown to correlate with insulin sensitivity assessed by clamp.[30] Insulin resistance was 
also assessed using homeostatic model assessment (Fasting plasma glucose – fasting plasma insulin 
divided by 22.5).  
Beta-cell function was assessed as the total insulin secretion during the OGTT (ISRtot) and beta-cell 
glucose sensitivity (GluSens), which reflects the response to changes in glucose levels. Furthermore, 
the ratio between the incremental insulin secretions assessed using C-peptide and plasma glucose 
concentration in the first 8 minutes after the intravenous glucose bolus were used to determine the 
acute insulin response (AIR) during IVGTT.  
Statistics 
Data are presented as percentages, and as mean (standard deviation) or median (interquartile 
range) as appropriate. First, the study population was stratified into two groups according to the 
glycaemic status, NGT or IGR. Second, differences in baseline anthropometrics as well as 
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measurements of fasting and insulin-stimulated levels of bone turnover markers and glucose 
homeostasis between individuals with NGT or IGR were investigated using Student’s t-test, Mann-
Whitney’s test and Chi-square tests. Third, the associations between bone turnover markers and 
measures of insulin sensitivity and secretion were assessed using Lowess-plots and regression 
analyses. For the regression analyses, three different regression models were used: 1) adjusted for 
recruitment centre 2) further adjustment for age and BMI 3) further adjustment for smoking and 
physical activity (measured as a continuous variable) for the entire study population, and then for 
the normal glucose tolerance and the impaired glucose regulation groups. Skewed variables were 
log transformed prior to performing the regression analyses, which were performed with the 
available data and without imputations as data were assumed to be missing at random. These 
regression analyses were performed for the complete study population as no interaction between 
glycaemic statuses was observed. The regression models were repeated with adjustment for 25-
OHD levels (continuous measure) or after restriction of the analyses to participants with normal 
levels of 25-OHD as well as used to test if baseline bone turnover markers predicted changes in 
fasting plasma glucose, 2-hour glucose and measures of insulin sensitivity and secretion. Fourth, 
changes in bone turnover markers during the clamp were evaluated using Student’s t-test (paired 
data). Significance was accepted at P < 0.05. 
Calculations were performed using STATA, v. 14 (StataCorp, College Station, Tx, US).  
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Results 
Baseline anthropometrics and life style factors 
Characteristics of the study population are presented in Table 1. None of the participants were 
treated with corticosteroids or anti-resorptive drugs. Among the 576 non-diabetic men, 503 (87%) 
had NGT and 73 IGR. Age, body weight and BMI were higher in individuals with IGR (Table 1). 
Neither physical activity nor tobacco use differed between individuals with NGT and IGR (Table 1).  
Glucose homeostasis 
Insulin sensitivity assessed from the OGTT (OGIS-RISC) or from the hyperinsulinaemic 
euglycaemic clamp (M/I) was higher and HOMA-IR lower in individuals with NGT (Table 2). 
Participants with NGT had lower ISRtot and higher GluSens during the OGTT than those with IGR 
(Table 2), while no difference in AIR during the IVGTT was observed between these groups.  
The OGTT was repeated in 468 of the 576 (73%) participants after three years. Fasting plasma 
glucose (+0.2 mmol/L, p<0.001) and fasting serum insulin (+2 pmol/L, p<0.01) were slightly 
increased after 3-years follow-up. Moreover, ISRtot was increased (+2 pmol/L, p<0.001), insulin 
sensitivity assessed by OGIS-RISC was reduced (-0.3 μmol / min / KgFFM, p<0.01), and HOMA-IR 
was increased (+0.6, p<0.001) after three years (Table 2). Significant changes in these outcomes at 
follow-up were observed only in individuals with NGT, possibly due to lower number of 
individuals with IGR (Table 2).  
Bone turnover markers 
No differences in fasting levels of CTX and P1NP were observed between individuals with NGT 
and IGR (Table 1). After 120 minutes of insulin stimulation (during the clamp), CTX and P1NP 
levels had decreased by 8.0% (p<0.001) and 1.9% (p<0.01), respectively (Fig. 1). Decreases in both 
CTX and P1NP during insulin stimulation were observed in individuals with NGT, whereas only 
CTX decreased significantly in individuals with IGR (Table 1). Vitamin D was measured in 77% 
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(n=451) of the participants. Vitamin D deficiency defined as a serum 25-OHD below 20 ng/dl was 
observed in 47% (n=211) of the study population, and the prevalence of vitamin D deficiency was 
comparable in individuals with NGT and IGR (Table 1). 
Relationship between bone turnover and glucose homeostasis 
Both CTX and P1NP were inversely associated with fasting plasma glucose in the study population 
before and after adjustment for potential confounders, but these relations were not reflected in an 
association between bone turnover markers and fasting levels of serum insulin (Table 3).  
The relationships between bone turnover markers and measures of insulin sensitivity (OGIS-RISC 
and Log-M/I) as well estimates of insulin secretion during IVGTT (AIR) and OGTT (ISRtot and 
GluSens) were first explored using Lowess plots (Supplementary material, a-f) but none of these 
plots pointed towards associations. 
Nevertheless, insulin sensitivity determined by OGIS-RISC was directly associated with both bone 
turnover markers in the complete study population. However, the association disappeared after 
inclusion of age and BMI in the regression models (Table 3). Neither of the bone turnover markers 
was associated with hyperinsulinaemic euglycaemic clamp-based measurements of insulin 
sensitivity (M/I) in unadjusted models. Insulin resistance assessed using the HOMA-IR was 
inversely associated with both CTX and P1NP in unadjusted analyses and remained inversely 
associated with P1NP but not CTX in the fully adjusted models. While insulin secretion during the 
IVGTT (AIR) was not associated with bone turnover markers either before or after adjustments, 
ISRtot during the OGTT was inversely associated with levels of P1NP in unadjusted but not adjusted 
models (Table 3).  
As vitamin D deficiency could interfere with the assessment of a relationship between bone 
turnover markers and glucose homeostasis, regression analyses were repeated with adjustments for 
vitamin D levels (as a continuous variable) and in participants that were vitamin D replete (25-OHD 
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≥ 20 ng/dl), however, neither of the results of the regression analyses changed noticeably after these 
adjustments (data not shown).   
Bone turnover markers and changes in insulin sensitivity and secretion 
Baseline levels of neither P1NP nor CTX were associated with increases in fasting plasma glucose 
levels during follow-up (Table 4). Baseline levels of CTX and P1NP were not associated with 
changes in fasting serum insulin levels, ISRtot, OGIS-RISC, or HOMA-IR during follow-up (Table 
4). 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 12 
Discussion 
The primary aim of this study was to investigate if bone turnover and insulin secretion and 
sensitivity are integrated in humans as expected, based on previous animal studies. We expected 
that levels of bone formation and resorption markers would be directly associated with insulin 
secretion, but neither of the bone turnover markers investigated were associated with insulin 
secretion capacity assessed using the IVGTT and the OGTT. Equally, we did not observe any 
relation between bone turnover markers and insulin sensitivity assessed using OGTT and the gold-
standard method, i.e. hyperinsulinaemic euglycaemic clamp. Therefore, these results demonstrate 
that bone turnover assessed using bone turnover markers and peripheral insulin sensitivity and 
insulin secretion are unrelated in healthy, non-diabetic men.  
Our observations are not in complete alignment with previous investigations. An inverse association 
between bone formation assessed using P1NP and insulin sensitivity determined using an IVGTT 
and a direct association between P1NP and insulin resistance based on HOMA-IR was observed in 
63 men and women with NGT or IFG.[31] While we detected an inverse relation between P1NP 
and insulin sensitivity based on hyperinsulinaemic euglycaemic clamp in individuals with IGR, the 
association was only present after adjustments. These differences in observations may be explained 
by skeletal muscle or hepatic insulin resistance that leads to fasting hyperinsulinaemia, which 
promotes bone formation, or insulin resistance in bone, that impairs bone turnover. Furthermore, an 
inverse association between insulin resistance determined using HOMA-IR and bone resorption 
(CTX) but not formation (P1NP) was detected in 2955 elderly men, but neither of these bone 
turnover markers was associated with insulin resistance after adjustment for age, BMI and 
comorbidities.[17] Further, P1NP was directly associated with insulin resistance assessed on the 
basis of HOMA-IR in 1010 Swedish men aged 70-81 years prior to but not after adjustment for 
osteocalcin levels, suggesting that osteocalcin but not P1NP is independently associated with 
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glucose homeostasis.[32] In addition, urinary NTX, a bone resorption marker, was not associated 
with fasting plasma glucose, whereas the level of osteocalcin was inversely associated with fasting 
plasma glucose in 380 elderly men.[13] Jointly, these previous investigations do not consistently 
support an association between BMTs such as P1NP and CTX and glucose homeostasis. In light of 
the results of the present investigation, which relies on measurements of insulin sensitivity assessed 
on the basis of both OGTT and hyperinsulinaemic euglycaemic clamp, evidence of an independent 
relationship between bone turnover markers and insulin sensitivity or indeed secretion is limited.  
By contrast, levels of osteocalcin appear to represent more than just bone formation. Accordingly, 
undercarboxylated osteocalcin and total osteocalcin are inversely associated with fasting plasma 
glucose and insulin resistance and directly associated with insulin sensitivity in humans investigated 
using OGTT and hyperinsulinaemic euglycaemic clamp.[13, 15, 32-35] These results emphasize 
that undercarboxylated osteocalcin and osteocalcin may reflect functions beyond that of bone 
remodelling. Furthermore, osteocalcin and undercarboxylated osteocalcin may predict changes in 
glucose levels or development of T2D according to some[13, 16, 17, 36] but not all prospective 
investigations.[20-22] Osteocalcin was not measured in the present investigation as osteocalcin is 
sensitivity to degradation, prompting blood samples for osteocalcin measurements to be chilled at 4 
degrees Celsius immediately after being collected, which was not part of the protocol in our 
investigation.[37] Furthermore, assays that measure bioactive osteocalcin, i.e. osteocalcin 
decarboxylated specifically at residue Glu17, are unavailable in humans.[38] The potential 
integration of bone and glucose homeostasis in humans needs to be assessed using other 
biochemical markers that may not portray the physiological effects of alterations in levels of 
bioactive osteocalcin during bone remodelling. Rather than assessing osteocalcin, we investigated 
the ability of commonly used bone turnover markers to predict alterations in glucose homeostasis 
during a short follow-up period. In keeping with the cross-sectional data, bone turnover markers 
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were not associated with changes in insulin sensitivity or insulin secretion after 3-years follow-up; 
suggesting that bone turnover per se and glucose homeostasis are unrelated in healthy men.  
The majority of previous clinical investigations have reported lower levels of bone turnover 
markers in individuals with type 1 or 2 diabetes than in controls.[26] Therefore, in order to 
investigate the relationship between bone turnover markers and glucose, insulin sensitivity and 
secretion independently of overt hyperglycaemia, patients with any type of diabetes were excluded 
from the present study. Although most of the study participants were glucose tolerant, a 
considerable number of participants had an abnormal glucose regulation. However, bone turnover 
markers were similar in those classified as either NGT or IGR suggesting that they may remain 
normal at least until development of overt hyperglycaemia.  
Investigation of the impact of long-term fasting hyperinsulinaemia without concurrent 
hyperglycaemia in human poses obvious difficulties. The acute effect of insulin on bone turnover 
has been investigated in a limited number of clinical studies by using hyperinsulinaemic 
euglycaemic clamps that involved different rates and durations of insulin infusion, i.e. 40 mU/m
2
 
per min, 80 mU/m
2
 per min or 0.5 mU/kg total body weight per min. Exposure to these levels of 
insulin had no apparent imminent effect on bone turnover assessed using bone turnover 
markers.[39-41] By contrast, a reduced bone resorption has been reported in hyperinsulinaemic 
euglycaemic clamps that were either of extended duration (40 mU/m
2
 per min; 4 hours), and 
hyperinsulinaemic hypoglycaemic clamps (80 mU/m
2
 per min; BG reduced to 2.5 nM).[39, 41] 
Importantly, these investigations included relatively small study populations that differed with 
regard to age, body composition and presence of T2D. Notably, the design of the clamp applied in 
the study by Basu et al.[40] that included 7 individuals with T2D and 7 controls relied on a different 
study design as secretion of pancreatic hormones during the clamp was prevented by infusion of 
somatostatin, growth hormone and glucagon, and insulin was infused at three different rates in 
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order to imitate the physiological range of insulin. While the investigators detected an association 
between levels of CTX and insulin sensitivity, after adjustment for BMI, the relationship was no 
longer significant, indicating that bone turnover and insulin sensitivity assessed during the clamp 
with control for potentially confounding secretions of pancreatic hormones known to influence 
glucose homeostasis and bone metabolism are distinct. However, while bone turnover markers 
seemingly remain fairly unchanged by insulin at physiological levels during a euglycaemic clamp, 
Clowes et al.[41] observed a substantial reduction in bone turnover markers during a 
hypoglycaemic clamp performed using similar levels of insulin, possibly explained according to the 
investigators by inhibitory effects of hypoglycaemia on bone cells, hormones counteracting 
hyperglycaemia or reductions in PTH levels observed during the hypoglycaemia.  
We observed decreases in the level of CTX and minor reductions in P1NP levels during a 2-hour 
hyperinsulinaemic euglycaemic clamp, which by design was similar to some of the studies that 
reported steady levels of bone turnover markers during insulin exposure. This disagreement may be 
explained by several factors including differences in the characteristics of the study population as 
the present investigation included substantially more individuals and was restricted to non-diabetic 
men, which may have reduced the variation, allowing us to identify alterations in bone turnover 
markers levels during insulin exposure. The overall effect of insulin on bone cell activity remains 
uncertain[42]. The decrease in P1NP and CTX during the clamp could be explained by several 
factors, including reduced levels of hormones known to promote bone activity such as IGF-1 or 
IGF-1 binding proteins, alterations in clearance of the bone turnover markers or inhibitory effects 
on osteoclasts activity, which leads to decreased osteoblast activity. CTX did not decrease in 
participants with IGR, but similar numerical changes in CTX levels were observed before and after 
insulin-stimulation, indicating that the discrepancy in CTX levels in the response to insulin 
stimulation between NGT and IGR could be explained by lower power. Importantly, 
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hyperinsulinaemic euglycaemic clamps relies on physiological insulin levels that are sustained 
beyond that observed in normal physiology; therefore, these changes in bone turnover markers may 
not represent the effects of physiological levels of insulin on bone turnover. Furthermore, the 
observed reductions in bone turnover markers are markedly smaller than those observed during 
consumption of food,[43] suggesting that the overall acute effect of intravenously administered 
insulin on bone turnover is minor.  
Several factors need consideration when the results of the present investigation are to be interpreted. 
We cannot exclude the possibility that the relationships between bone turnover markers and insulin 
secretion and sensitivity differ in individuals with manifest diabetes or in women. Furthermore, 
although adjustment for 25-OHD levels or restriction of the investigations to those that were 
vitamin D replete appeared not to change the results, it could be argued that the relationship 
between bone turnover markers and glucose homeostasis may vary between those with low and 
normal levels of vitamin D. Because BMD was not measured, we were unable to assess if the 
relationship between bone turnover markers and glucose homeostasis differed between individuals 
with high or low bone mass. Finally, although the size of the study population provided sufficient 
power to investigate the main aims, i.e. the relationships between bone turnover markers and insulin 
sensitivity and secretion, several comparisons without simultaneous adjustment for multiple testing 
were performed, which invariably increases the risk of spurious findings. 
Conclusions 
The present investigation showed that levels of commonly used biochemical markers of bone 
formation and resorption are not associated with insulin sensitivity and secretion assessed by use of 
different tests including hyperinsulinaemic euglycaemic clamp, IVGTT and OGTT in a very large 
study population of carefully characterized, non-diabetic men. Additionally, we did not observe any 
relationship between baseline bone turnover markers and 3-year changes in insulin sensitivity and 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 17 
secretion. Jointly, these results do not support the notion that bone turnover and glucose 
homeostasis are integrated in adult men. When possible, it needs to be investigated if levels of 
bioactive osteocalcin are associated with glucose homeostasis in adult non-diabetic individuals.  
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Figure legend 
 
Fig. 1 
Bone turnover markers measured in the fasting state and after insulin stimulation (120 min) during a 
hyperinsulinaemic euglycaemic clamp in 567 non-diabetic adult men (ALL) with normal glucose 
tolerance (NGT; n=503) or impaired glucose regulation (IGR; n=73). Data are mean (standard 
deviation). 
§§§
P<0.001 and 
§§
P<0.01 versus fasting.  
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Table 1. Basic anthropometrics, life style factors and bone turnover markers in men. The EGIR-RISC Study 
 
  
All 
n=576 
 
NGT 
n=503 
 
IGR 
n = 73 
 
p-value 
(comparison of 
glycaemic 
groups) 
 
Anthropometrics 
 
Age (years) 42 (36-49) 42 (36-49) 47 (39-51) 0.028 
BMI (kg/m
2
) 26.2 (3.5) 26.1 (3.4) 27.9 (3.4) <0.001 
Smokers (%) 28% 28% 32% 0.717 
 
Physical activity 
 
n=503 
 
n=482 
 
n=69 
 
Physical activity 
1: inactive 
2: minimally active 
3: health enhancing activities 
Data available in 551 individuals 
 
1: 21% 
2: 42% 
3: 37% 
 
20% 
42% 
38% 
 
26% 
42% 
32% 
 
 
 
<0.001 
METS per week  2300 (960-
4668) 
2253 (990-
4746) 
2475 (735-
4158) 
0.465 
 
Vitamin D levels 
 
n=445 
 
n=397 
 
n=48 
 
Vitamin D (ng/dl) 21.1 (10.2) 21.3 (10.2) 20.0 (10.0) 0.413 
Vitamin D deficiency % 
25-OHD <20 ng/dl 
47% 46% 58% 0.109 
 
Bone turnover markers 
 
Fasting serum CTX (µg/L) 466 (172) 468 (170) 461 (194) 0.719 
Fasting serum P1NP (µg/L) 49 (17) 49 (17) 48 (18) 0.629 
Insulin-stimulated serum CTX (µg/L) 428 (157)
 §§§
 430 (157)
§§§
 418 (156)
 
 0.546 
Insulin-stimulated serum P1NP (µg/L) 48 (17)
 §§
 48 (17)
 §§
 47 (17) 0.541 
 
Comparison of bone turnover markers at baseline and at 3-years: 
 §
p<0.05, 
§§
p<0.01 and 
§§§
p<0.001. 
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Table 2. Glucose homeostasis at baseline and at 3-years of follow-up in men. The EGIR-RISC Study. 
 
  
All 
n=576 
 
NGT 
n=503 
 
IGR 
n=73 
 
p-value 
(comparison 
of glycaemic 
groups) 
 
Glucose homeostasis at baseline 
Fasting plasma glucose (mmol/L) 5.2 (0.5) 5.2 (0.5) 5.7 (0.6) <0.001 
120 min plasma glucose (mmol/L) 5.7 (1.4) 5.4 (1.1) 7.6 (1.5) <0.001 
Fasting serum insulin (pmol/L) 32 (22-47) 31 (21-45) 47 (33-67) <0.001 
120 min serum insulin (pmol/L) 131 (75-230) 122 (68-210) 286 (160-509) <0.001 
Total insulin secretion (OGTT) 41 (15) 40 (14) 50 (17) <0.001 
GluSens (pmol / min / m
2
 mM) 102.3 (74.2-139.1) 107 (78-142) 78 (57-102) <0.001 
OGIS-RISC (μmol / min / kg FFM) 10.2 (1.9) 10.4 (1.8) 8.3 (1.4) <0.001 
HOMA-IR 1.4 (0.8-1.9) 1.4 (0.8-1.8) 2.1 (1.3-2.7) <0.001 
M/I (μmol / kg FFM / min / nmol/l) 111.9 (81.4-151.5) 116 (85-156) 86 (62-126) <0.001 
  
n=438 
 
n=380 
 
n=58 
 
AIR (pmol/L) (IVGTT) 790 (486-1133) 802 (501-1152) 701 (414-1002) 0.112 
 
Glucose homeostasis at follow-up 
  
n=461 
 
n=413 
 
n=48 
 
Fasting plasma glucose (mmol/L) 5.4 (0.6)
 §§§
 5.3 (0.6)
 §§§
 5.6 (0.6) <0.001 
Fasting serum insulin (pmol/L) 33 (24-49)
 §§
 33 (23-47)
§§§
 39 (27-59) 0.093 
Total insulin secretion (OGTT) 43 (15)
§§§
 42 (15)
 §§§
 46 (18) 0.179 
HOMA-IR 1.6 (0.9-2.0)
 §§§
 1.6 (0.9-1.9)
 §§§
 1.9 (1.1-2.5) 0.027 
OGIS-RISC (μmol / min / kg FFM) 9.9 (2.1)
 §§
 10.1 (2.1)
  §§§
 9.0 (1.9) 0.001 
GluSens (pmol / min / m
2
 mM)  107 (78-140) 109 (85-149) 74 (59-87) <0.001 
 
Comparison of glucose homeostasis at baseline and at 3-years: 
 §
p<0.05, 
§§
p<0.01 and 
§§§
p<0.001  
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Table 3. Regression coefficients (95% confidence intervals) between bone turnover markers and measures 
of glucose homeostasis at baseline, according to glucose tolerance status.  B The EGIR-RISC Study 
 
  
 CTX (ng/L) 
 
P1NP (ng/L) 
 
 All p-value All p-value 
 
Adjusted for centre 
Fasting plasma glucose (mmol/L) -53.7
 
(-81.9;  -25.4) <0.001 -5.1 (-7.9; -2.3) <0.001 
Fasting serum insulin (pmol/L) -0.4 (-1.1; 0.3) 0.280 -0.1 (-0.1; 0.0) 0.082 
Log AIR (pmol/L)  15.7 (-6.5; 37.8) 0.165 1.1 (-1.1; 3.2) 0.326 
Total insulin secretion (OGTT) -0.2 (-1.3; 0.7) 0.570 -0.1 (-0.2; -0.1) 0.017 
Log GluSens (pmol / min / m
2
 mM) 16.8 (-8.6; 42.2) 0.195 0.7 (-1.8; 3.3) 0.571 
Log M/I (μmol / kg FFM / min / nmol/l) 2.7 (-24.9; 30.4) 0.845 1.4 (-1.3; 4.2) 0.306 
OGIS-RISC (μmol / min / kg FFM) 12.4 (4.9; 19.9) 0.001 1.0 (0.3; 1.8) 0.007 
Log HOMA-IR -36.3 (-61.3; -11.3) 0.004 -3.6 (-6.1; -1.1) 0.005 
 
Adjusted for age, BMI and centre 
Fasting plasma glucose (mmol/L) -36.9 (-65.5; -8.3) 0.011 -3.2 (-6.0; -0.4)  0.028 
Fasting serum insulin (pmol/L) 0.5 (-0.3; 1.3) 0.198 0.0 (-0.1; 0.1) 0.702 
Log AIR (pmol/L) 17.9 (-4.2; 40.1) 0.112 0.9 (-1.2; 3.1) 0.400 
Total insulin secretion (OGTT) 0.7 (-0.3; 1.7) 0.180 -0.0 (-0.1; 0.1) 0.524 
Log GluSens (pmol / min / m
2
 mM) 12.2 (-12.7; 37.1) 0.335 0.2 (-2.3; 2.6) 0.889 
Log M/I (μmol / kg FFM / min / nmol/l) -36.1 (-66.6; -5.6) 0.020 -1.9 (-4.9; 1.2) 0.225 
OGIS-RISC (μmol / min / kg FFM) 3.9 (-4.9; 12.6) 0.384 0.1 (-0.8; 1.0) 0.824 
Log HOMA-IR -9.4 (-37.8; 19.1) 0.518 -1.0 (-3.9; 1.8) 0.474 
 
Adjusted for age, BMI, smoking, physical activity and centre. 
Fasting plasma glucose (mmol/L) -49.1 (-86.3; -11.9) 0.010 -5.8 (-9.7; -1.9) 0.004 
Fasting serum insulin (pmol/L) -0.1 (-1.2; 1.0) 0.801 -0.1 (-2.9; 2.8) 0.955 
Log AIR (pmol/L) 11.6 (-16.1; 39.3) 0.410 -0.1 (-0.2; 0.1) 0.327 
Total insulin secretion (OGTT) 0.2 (-0.2; 1.6) 0.817 -0.1 (-0.2; 0.1) 0.220 
Log GluSens (pmol / min / m
2
 mM) 5.7 (-26.5; 37.9) 0.729 -0.7 (-4.1; 2.7) 0.674 
Log M/I (μmol / kg FFM / min / nmol/l) -27.5 (-65.7; 10.7) 0.158 -1.7 (-5.8; 2.3) 0.392 
OGIS-RISC (μmol / min / kg FFM) 5.2 (-5.6; 16.1) 0.345 0.4 (-0.8; 1.5) 0.506 
Log HOMA-IR -31.2 (-69.0; 6.5) 0.104 -4.1 (-8.1; -0.1) 0.043 
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Table 4. Change in per cent from baseline of measures of glucose homeostasis and regression coefficients 
(95% confidence intervals) between baseline bone turnover marker levels and delta values of measures of 
glucose homeostasis. The EGIR-RISC Study 
 
  
Δ  Fasting 
plasma 
glucose 
(mmol/L) 
 
Δ Fasting 
serum 
insulin 
(pmol/L) 
 
Δ Total 
insulin 
secretion 
(OGTT) 
 
Δ GluSens 
(pmol / min / 
m
2
 mM) 
 
Δ OGIS 
(μmol / min / 
kg FFM) 
 
Δ HOMA-IR 
  
n=468 
 
n=439 
 
n=415 
 
n=415 
 
n=398 
 
n=437 
% change 
from baseline  
 
+2.9% 
 
+8.4% 
 
+6.8% 
 
+1.5% 
 
-3.0% 
 
+11.2% 
 
Bone turnover markers  
CTX (µg/L) # 0.002  
(-0.001; 
0.001) 
0.001  
(-0.011; 
0.011)  
-0.003  
(-0.009; 
0.004) 
-0.012  
(-0.051; 
0.027) 
-0.001  
(-0.001; 
0.001) 
0.001  
(-0.001; 
0.001) 
P1NP (µg/L) # -0.001  
(-0.004; 
0.002) 
-0.022  
(-0.126; 
0.823) 
-0.012  
(-0.076; 
0.053) 
0.122  
(-0.267; 
0.511) 
0.005  
(-0.004; 
0.014) 
-0.001  
(-0.006; 
0.003) 
Adjusted for centre, age, BMI, smoker and physical activity. 
CTX (µg/L)
 ##
 0.001 
(0.000; 
0.001)* 
-0.003  
(-0.015; 
0.009) 
-0.001  
(-0.008; 
0.005) 
-0.001  
(-0.050; 
0.031) 
-0.001  
(-0.001; 
0.001) 
-0.001  
(-0.001; 
0.001) 
P1NP (µg/L)
 ##
 0.001  
(-0.003; 
0.003) 
-0.038  
(-0.150; 
0.075) 
-0.004  
(-0.072; 
0.064) 
0.197  
(-0.199; 
0.593) 
0.003  
(-0.006; 
0.013) 
-0.001  
(-0.006; 
0.003) 
 
#Adjusted for recruitment centre. 
## 
Adjusted for centre, age, BMI, smoker, IPAQMETS.  
*
p<0.05. 
**
p<0.01 
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Highlights 
 
- Markers of bone formation and resorption P1NP and CTX were inversely associated with 
fasting plasma glucose in non-diabetic men. 
- There were no association between the same biochemical markers of bone turnover and 
insulin sensitivity and secretion assessed using euglycaemic, hyperinsulinaemic clamps and 
intravenous glucose tolerance tests 
- Levels of CTX and P1NP decreased during the clamp (by 8% and 2%, respectively). 
- Bone turnover markers do not predict changes in insulin sensitivity assessed using OGTT 
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